Flurpiridaz PET/CT
Phase 1
Flurpiridaz PET/CT is one of 4 therapeutic programs targeting Hyperparathyroidism. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Hyperparathyroidism
#DrugCompanyPhaseTrials
1Zemplar
AbbVieApproved
Calciferol
Jazz PharmaceuticalsPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Flurpiridaz PET/CT
UUniversity of Pennsylvania
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Flurpiridaz PET/CT. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Pennsylvania